Clinical Psychopharmacology and Neuroscience

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistance Depression and Major Depression with Suicide Ideation: A Meta-Analysis

This meta-analysis (s=7; n=1488) of double-blind placebo-controlled studies with those suffering from depression (MDD; TRD) and suicidal ideation (SI) found that esketamine (24-84mg) significantly improved scores on a measure of depression (MADRS) over the placebo up to 28 days alter, the SI scores were only significant within the first 24 hours.

Published

April 26, 2021

Journal

Clinical Psychopharmacology and Neuroscience

Authors

Bahk, W., Wang, S., Kim, N., Lim, H., Woo, Y., Pae, C., Na, H.